Cardiovascular safety from prostate cancer drugs remains uncertain

Worldwide, over one million men are diagnosed with prostate cancer every year, and half will be given androgen deprivation therapy at some point. Whether certain types of this therapy are safer for the heart than others is an important question that is being studied, but the results from the first such trial were inconclusive and disappointing.